GaitherJRLeventhalJMRyanSACamengaDR.National trends in hospitalizations for opioid poisonings among children and adolescents, 1997 to 2012. JAMA Pediatr. 2016;170(12):1195-1201. doi:10.1001/jamapediatrics.2016.2154.
2.
AllenJDCasavantMJSpillerHAChounthirathTHodgesNLSmithGA.Prescription opioid exposures among children and adolescents in the United States: 2000-2015. Pediatrics. 2017;139(4):e20163382. doi:10.1542/peds.2016-3382.
3.
PatrickSWFryCEJonesTFBuntinMB.Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff. 2016;35(7):1324-1332. doi:10.1377/hlthaff.2015.1496.
4.
Greenwood-EricksenMBPoonSJNelsonLSWeinerSGSchuurJD.Best practices for prescription drug monitoring programs in the emergency department setting: results of an expert panel. Ann Emerg Med. 2016;67(6):755-764. doi:10.1016/j.annemergmed.2015.10.019.
ReistJFrazierJRottinghamAWelshMViyyuriBRWitryM.Provider beliefs on the barriers and facilitators to prescription monitoring programs and mandated use. Subst Use Misuse. 2020;55(1):1-11. doi:10.1080/10826084.2019.1648512.
7.
WangGSRooseveltGFaganKHoppeJ.Pediatric emergency physician knowledge and utilization of prescription drug monitoring program. Clin Pediatr. 2017;56(1):80-82. doi:10.1177/0009922816638508.
8.
EarlywineJJHadlandSERaifmanJ.State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995-2017: a difference-in-differences analysis. PLoS Med. 2020;17(9):e1003272. doi:10.1371/journal.pmed.1003272.
DeyoRAHallvikSEHildebranC, et al. Association of prescription drug monitoring program use with opioid prescribing and health outcomes: a comparison of program users and nonusers. J Pain. 2018;19(2):166-177. doi:10.1016/j.jpain.2017.10.001.
12.
DowellDHaegerichTMChouR.CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464.
